CER Daily Newsfeed

Editor’s Highlights from the Journal of Comparative Effectiveness Research – October 2023

(10/10, Laura Dormer, The Evidence Base) comments “I’m pleased to share some of my highlights from the October issue of the Journal of Comparative Effectiveness Research (JCER)...This issue includes the first installment of a new series of Industry Update articles on market access, an Institute for Clinical and Economic Review (ICER) White Paper on provider markup in the commercial insurance market, research on the real-world impact of patient-reported outcome (PRO) measurement in cancer patients and a review of methodological approaches for indirect treatment comparisons (ITCs).” Full

Type 2 Diabetes Research Done Differently: Studying Telemanagement for Hispanic and Latino Adults

(10/11, The PCORI Blog) comments “...[M]ost research on telehealth programs to treat type 2 diabetes has not tailored technologies and interventions specifically to fit the needs of the most affected or underserved groups, such as Hispanic or Latino adults. By studying the use of diabetes telemanagement, which allows patients to track their vital signs and share information with their healthcare team through a smart device, a PCORI-funded study is aiming to fill in some of the gaps in attention and care for Hispanic and Latino adults living with type 2 diabetes.” Full

Why Are Haemophilia Gene Therapies So Expensive?

(10/11, Irena Maragkou, Pharmaceutical Technology) reports “...While ICER found these therapies to be cost-effective, their first policy recommendation emphasises that assessing the value of short-term treatments should not be offset or solely rely on long-term cost savings predictions, especially when the current standard of care has unreasonably high prices.” Full

German HTA: EMA Single-Arm Trial Paper Lets Down Patients & Developers

(10/11, Francesca Bruce, Pink Sheet) reports “...The EMA should look to the US FDA for recommendations on external controls, advises the German HTA body, IQWiG.” Subscription Required